Matthew Foy

Matthew Foy has been CEO and Managing Partner of Avante Biocapital since June 2024, bringing over a decade of transatlantic biotech experience, including 15 years at SR One Capital Management, the venture firm spun out of GSK in 2020. He serves as Investor Director at Econic Biosciences and Xap Therapeutics, and sits on the boards of Fore Biotherapeutics and Pulmocide. Alongside his investment work, he's been a consultant and seed investor at PRESS London since 2015, and a patron of emerging artists since 2018.